The Teva Pharmaceuticals affiliate’s digital health platform is a cloud-based backend data system designed to support its FDA-approved Digihaler portfolio of breath-actuated digital inhalers and its companion mobile app that tracks inhaler events and measures inspiratory flow, according to a news release.
Onica’s development team supported the construction of the platform, allowing the system to fully leverage the cloud capabilities of AWS, allowing for extreme scalability, resiliency and cost-effectiveness, the companies say.
“We’re pleased to bring together AWS’s unmatched portfolio of services with Teva’s long-standing respiratory reputation and expertise to now provide objective inhaler use data which may help inform physicians in the care and treatment of patients,” AWS director of worldwide business development for healthcare, life sciences & genomics Dr. Shez Partovi said in the release. “Teva’s approach to providing patients with access to and control of sharing their inhaler event data with their healthcare provider has the potential to impact and inform how patient care is delivered, and specifically, within the asthma and chronic obstructive pulmonary disease (COPD) disease states.”
The cloud system is designed to allow users to view stored information on their Digihaler events through the companion app, which can link to multiple inhaler devices. Patients can review data over time and receive notifications while also remaining capable of sharing data with healthcare providers to inform treatment decisions.
“With our Digihaler products now being commercially available to patients, ensuring data security is paramount,” Teva Pharmaceuticals executive VP of global marketing & portfolio Sven Dethlefs said. “With digital health and remote monitoring emerging as vital elements of patient care, we are excited to be working with AWS and Onica who are experienced in ensuring patients’ information is secure while easily accessible to them.”